ArticleThoracic cancer2026
Histone Variant H2A.Z2 Hyper-Transcription Induced by E2F1 Accelerates Lung Adenocarcinoma Progression via the JAK-STAT Signaling Pathway.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is among the most common cancers and a leading cause of cancer-related deaths. The histone variant H2A.Z has two isoforms (H2A.Z1 and H2A.Z2) encoded by distinct paralogs. Increasing numbers of evidence have demonstrated that H2A.Z1 and H2A.Z2 play a critical role in the pathogenesis of various cancers. Nevertheless, the precise biological functions and underlying mechanisms of H2A.Z in LUAD remain unclear.
methodsThe levels of H2A.Z expression in LUAD were evaluated using immunohistochemistry (IHC) and western blot assays. To investigate the biological role of H2A.Z2 in LUAD cells, both in vitro and in vivo experiments were conducted. To evaluate gene expression alterations and predict downstream pathways, transcriptome sequencing was performed. To validate that E2F transcription factor 1 (E2F1) regulates H2A.Z2 expression, dual luciferase reporter assays and chromatin immunoprecipitation (ChIP) assays were used.
resultsHerein, we demonstrated high expression pattern of H2A.Z in LUAD tissues and its correlation with adverse clinical outcomes. Functionally, we indicated that H2A.Z2 exerts an oncogenic function in driving LUAD cell proliferation and metastasis. Mechanistically, analysis based on transcriptome sequencing suggested the influence of H2A.Z2 on the JAK-STAT pathway. Rescue experiments revealed that H2A.Z2 promotes LUAD progression by modulating STAT5B. Furthermore, we identified E2F1 as an activator that binds to the H2A.Z2 promoter to drive its transcription, thereby providing a novel mechanism of H2A.Z2 dysregulation.
conclusionsIn conclusion, our findings revealed a novel E2F1/H2A.Z2/STAT5B axis accelerating LUAD malignance, suggesting its potential as a promising target for diagnostic and therapeutic interventions in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.